Thomas T.H. Chou

Represented SoftBank in its US$9.6 billion investment in Xiaoju Kuaizhi Inc. (DiDi), China’s leading ride–hailing and mobile transportation platform.

Represented Trusted Doctors (Xingren) in its strategic merger agreement with Tencent Doctorwork. The newly formed venture, which is named Tencent Trusted Doctors, will offer an ecosystem of both online and offline services devoted to leveraging Internet technology to provide high–quality and accessible healthcare service to customers all over the country.

Represented Oriente in its US$105 million initial funding round. The deal is reported to be one of the largest initial funding rounds by any startup in Asia and also for a FinTech company worldwide.

Represented Ally Bridge Group as lead investor in connection with numerous investments in various life sciences companies, including 1) US$300 million equity financing in Grail, Inc., a company developing a blood test to detect cancer before symptoms appear; 2) a US$65 million equity financing in 2019 and subsequent $66 million financing in 2020 in PulmonX, a U.S. based medical technology company specializing in lung cancer; 3) a $60 million equity investment in Rapid Micro Biosystems, Inc., a U.S.-based medical products manufacturer; 4) $27 million equity investment in Venclose, Inc., a U.S. based medical technology company; 5) $25 million investment in Vida Health, Inc., a U.S.-based leading virtual care platform.

Represented Happiness Capital as one of the investors in the $125 million Series C financing in Ÿnsect, French ag–tech innovator that specializes in breeding insects and transforming them into premium ingredients for fish feed, pet food, and organic plant fertilizers.

Represented a leading Chinese internet services company in multiple equity financings of a joint venture which offers a one–stop investment and wealth management platform for Chinese around the world. The JV company was licensed for asset management and securities advisory by the Hong Kong’s SFC.

Represented Asteri Networks in its initial convertible note financings from Asia–based investors.

Represented CLSA and a consortium of investors in relation to the Series C round investment into the ACT Genomics Group. Based in Taiwan, and with operations across Asia (Singapore, Japan, Hong Kong, PRC), ACT Genomics provides genomic profiling assays, molecular information to physicians and biopharmaceutical clients, and cancer treatment plans, cancer relapse, and drug resistance monitoring, as well as cancer risk assessment and immunotherapy evaluation.

Representing Airbnb on its China market entry.

Representing Kirin Holdings Company, a leading Japanese company in the global food and beverage market, in its equity investment for a 24.5% stake Brooklyn Brewing Corporation, a craft beer manufacturer in Brooklyn, New York.